Phase I open label study to evaluate the safety and immunogenicity of heat-labile toxin (LT) vaccination [Escherichia coli vaccine] by transcutaneous immunisation (TCI) in the elderly and compare elderly immune responses with those developed by healthy adults

Trial Profile

Phase I open label study to evaluate the safety and immunogenicity of heat-labile toxin (LT) vaccination [Escherichia coli vaccine] by transcutaneous immunisation (TCI) in the elderly and compare elderly immune responses with those developed by healthy adults

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2013

At a glance

  • Drugs Heat-labile enterotoxin E coli (Primary)
  • Indications Enterotoxigenic Escherichia coli infections
  • Focus Adverse reactions
  • Sponsors Intercell USA
  • Most Recent Events

    • 05 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top